Charles River Laboratories International, Inc. $CRL Stock Bought by Russell Investments Group Ltd.

Charles River Laboratories International logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Russell Investments increased its Charles River Laboratories stake by 457.3% in the third quarter, adding 357,817 shares to hold 436,055 shares worth about $128.6 million.
  • Charles River reported quarterly EPS of $3.09, beating the $2.97 consensus, and revenue of $982.7 million, above estimates; revenue was down 2.2% year over year.
  • Analysts’ consensus rating was “Moderate Buy”, with an average price target of $311.67. Company insiders sold 63,352 shares worth about $20.3 million over the prior quarter.
  • Five stocks to consider instead of Charles River Laboratories International.

Russell Investments Group Ltd. increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 457.3% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 436,055 shares of the medical research company's stock after buying an additional 357,817 shares during the quarter. Russell Investments Group Ltd. owned about 0.91% of Charles River Laboratories International worth $128,641,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Amundi grew its stake in shares of Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company's stock worth $133,397,000 after acquiring an additional 492,301 shares during the period. Dimensional Fund Advisors LP lifted its position in Charles River Laboratories International by 14.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock valued at $285,001,000 after purchasing an additional 210,260 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Charles River Laboratories International by 230.9% in the third quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company's stock worth $59,044,000 after purchasing an additional 142,716 shares during the last quarter. Retirement Systems of Alabama grew its position in Charles River Laboratories International by 1,246.1% in the 3rd quarter. Retirement Systems of Alabama now owns 136,211 shares of the medical research company's stock worth $40,184,000 after purchasing an additional 126,092 shares during the period. Finally, State of Alaska Department of Revenue grew its position in Charles River Laboratories International by 2,268.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 111,781 shares of the medical research company's stock worth $32,977,000 after purchasing an additional 107,061 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Trading Up 0.1%

Shares of CRL stock opened at $338.27 on Monday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.41 and a quick ratio of 1.12. The company has a market cap of $16.21 billion, a price-to-earnings ratio of 371.73, a PEG ratio of 3.05 and a beta of 1.36. Charles River Laboratories International, Inc. has a 1 year low of $146.20 and a 1 year high of $379.63. The firm has a fifty day moving average price of $311.21 and a 200-day moving average price of $228.24.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, topping analysts' consensus estimates of $2.97 by $0.12. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The company had revenue of $982.73 million for the quarter, compared to analysts' expectations of $960.36 million. During the same period last year, the firm earned $2.43 EPS. Charles River Laboratories International's revenue for the quarter was down 2.2% compared to the same quarter last year. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Zacks Research lowered shares of Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a research note on Monday, November 2nd. Jefferies Financial Group upped their price objective on Charles River Laboratories International from $305.00 to $340.00 and gave the company a "buy" rating in a research report on Monday, September 28th. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a report on Monday, August 10th. Royal Bank Of Canada boosted their price target on Charles River Laboratories International from $322.00 to $352.00 and gave the company an "outperform" rating in a research note on Thursday, November 5th. Finally, Barclays upped their price target on shares of Charles River Laboratories International from $330.00 to $375.00 and gave the company an "overweight" rating in a research report on Thursday, November 5th. Thirteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $311.67.

View Our Latest Stock Analysis on CRL

Insider Transactions at Charles River Laboratories International

In related news, EVP Shannon M. Parisotto sold 2,156 shares of the stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the sale, the executive vice president directly owned 4,807 shares of the company's stock, valued at approximately $1,655,578.87. This represents a 30.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total transaction of $163,442.52. Following the completion of the sale, the director directly owned 1,438 shares of the company's stock, valued at $410,175.12. This represents a 28.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 63,352 shares of company stock valued at $20,291,281 over the last quarter. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

(Free Report)

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company's offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.

Read More

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Charles River Laboratories International Right Now?

Before you consider Charles River Laboratories International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.

While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines